Bonn, North Rhine-Westphalia, Germany
Based on our unique phenotypic screening capabilities, we have discovered a novel mechanism to potentially treat a-synucleinopathies in Parkinsons disease. We have unravelled the molecular target and are now in early leadoptimization. Now we are seeking funding to drive this drug discovery project towards IND. Interested in a novel mechanism for PD treatment? Come speak to us Dedicated drug hunter with 30 years industry experience and a proven track record in identifying high quality clinical candidates in various therapeutic areas and a marketed compound. Experience in Drug Discovery, Lead discovery, Chemical library development, Licensing, partnership building. Experience in setting up preclinical and early clinical concepts for rare disease indications , Biotech strategy consultant Proven track record and strong background in medicinal chemistry (inventor of a marketed product). Demonstrated Management and leadership skills with significant impact on pipeline, several late stage projects and marketed drugs (Levitra, Xarelto, Kerendia, Verquvo, Musredo, Adempas...) from Med Chem organisation. Set up and managed a 150Mill € library enhancement project. Very good communication skills, Dedicated team player, Spezialgebiete: Medicinal Chemistry, Enzyme inhibitors, Nuclear hormone receptors, Project management Portfolio management and control, Compound logistics, Oncology, Cardiovascular diseases, Organic synthesis, Lead Discovery strategies, Partnership building, Alliances, Licencing concepts
Head of the Medicinal Chemistry Department, Wuppertal. Lectureship Medicinal Chemistry, Technical University Dortmund
Successfully identified a clinical candidate in a rare genetic disease „primary hyperoxaluria“ and a preclinical candidate in autoimmune diseases